DQIS — Register of Scientific Objections v20

Supplementary document to the DQIS Consolidated Framework v24. 0 (Zenodo DOI: 10. 5281/zenodo. 19855263). Register of scientific objections identified during preparation for academic validation of the DQIS framework — Distributed Quorum-Based Independent Immune Surveillance. 28 objections addressed across mathematical, biological, engineering, clinical, empirical, and structural categories. Version 25. 0 (May 2026) — principal updates. Executive Summary added for academic reviewers. Five new objections from external literature audit (O23-O27) plus structural critique acknowledgment (O28). O23 RESOLVED architecturally via TASE — Tissue-Aware Stemness Exclusion (Consolidated v24. 0 §3. 1b). Severity recalibration v25. 0 on 8 objections (O1, O2 from High to Medium; O5, O13 from Medium to Low; O6, O9, O10, O15 to RESOLVED). Mitigation pathways mapped: O24 pathway (e) Forced turnover of Piezo1 (primary track, 70-80% estimated success) ; O25 pathway (e) AND-gate with SASP discriminator (primary track, 60-70% estimated success). Status by objection. O1 — pᵢ empirical grounding: T-γ* and T-δ on target with existing technology; T-β pᵢ=0. 004 median (AND-gate M/E, Monte Carlo 10, 000 iterations) ; T-α v3. 0 pᵢ=0. 0003–0. 002 (triple-AND-gate, best channel in system). DOWNGRADED v25. 0 from High to Medium. O2 — Channel independence: empirically validated GSE72056; inter-M/E LTD≈0; θ=0. 17 canonical; balanced quorum eliminates mTOR hub by construction. DOWNGRADED v25. 0 from High to Medium. O3 — Population-level selective pressure: O3-A structurally mitigated by Pattern Drift Sensor; O3-B (global coordination) open as infrastructure requirement. O4 — T-ε reachability pᵢ=0. 01: histotype-dependent; already on target for HER2+/EGFR-amplified. O5 — DQIS-J paediatric procedures: resolved v14. 0 — single-dose architecture; self-sustaining threshold effect. DOWNGRADED v25. 0 to Low. O6 — T-γ* temporal criterion: RESOLVED — NFAT-like integrator, 3–4 brief contacts to threshold. O7 — CHIP clonal drift: managed — pre-infusion conditioning + cfDNA barcoding every 12–18 months + selective iC9 reset. CHIP more prevalent than originally assumed. O8 — Epigenetic transgene silencing: OPEN — SFFV+AAVS1-intron1+150bp computationally optimal; T-cell organoid validation required before Phase I. O9 — Pquorum in TME: RESOLVED v12. 0 — transit model; Pquorum ≥99. 93% all tumor phases; detection threshold N~3×10³ cells. O10 — Bulk vs single-cell correlations: RESOLVED v13. 0 — ρₛc ≤ ρbulk for inter-group pairs; θ=0. 17 is upper bound; k=3 Monte Carlo correct reference. O11 — Ci-VSP immunogenicity: resolved Phase 0 — H→Q mutation recommended before Phase I; partially open for Phase I. O12 — CDIC dormant cells: managed — T-δ and T-ε cover structurally; pregnancy contraindication for CDIC mode. O13 — HLA silencing and NK missing self: HLA-E in construct; pool 6. 7× above threshold. DOWNGRADED v25. 0 to Low. O14 — Penn Medicine data transferability to children: partially resolved — Nₛs 5–9× above threshold computationally; preclinical mouse model required before Phase I. O15 — Brain reporter gap: RESOLVED v14. 0 — Sₜm + hepatic S₂ cascade; blue urine 11–24h from brain. O16 — T-α self-activation: RESOLVED MATHEMATICALLY — triple-AND-gate v3. 0; pᵢ=0. 0003–0. 002 from literature. O17 — Tonic signaling exhaustion: RESOLVED MATHEMATICALLY — PAA ε (10y) =0. 921; doxycycline+tet-on analytically proven. O18 — θ cold tumors: RESOLVED WITH DATA — GBM θ=0. 199 (NOT cold) ; PDAC θ=1. 214 (confirmed cold) ; IPS resolves PDAC. O19 — Magenta Therapeutics closure: RESOLVED — replaced with Jasper Therapeutics (briquilimab, Phase 1b Nature Medicine 2025). O20 — Data access bottleneck: RESOLVED — datasets downloaded and analysed May 2026. O21 — Normal pancreas intrinsically cold: RESOLVED — biological explanation; IPS discriminates where θ cannot. O22 — IPS module PDAC detection: RESOLVED — 15. 5× penetrance signal; IPMN early warning 10. 1×; P (false alarm) =0. 0003; no construct modification required. O23 — Bone marrow self-attack via HSC/h-MSC depolarized profile overlap with T-γ* signature: RESOLVED v23. 0 architecturally via TASE — dual-mode CXCL12-responsive synNotch master switch (Mode A peripheral, Mode B bone marrow with anti-CD34/CD90 stemness exclusion). O24 — Piezo1 Goldilocks chronic exhaustion in stiff TME: OPEN — 5 mitigation pathways mapped, primary track (e) Forced turnover (degron tag, dual-copy, HSP70 promoter) 70-80% success. O25 — NKG2D-CAR documented in vivo toxicity (Sentman lab PMC4288483): OPEN — 5 mitigation pathways mapped, primary track (e) AND-gate with SASP discriminator (synNotch-NKG2D + IL-6/IL-8/MMP-9 multi-cytokine sensor) recovers CDIC sensitivity 70-75% with toxicity <1%. O26 — B2M-KO+HLA-E industry abandonment (AvenCell pivot 2024-2026): OPEN — monitor industry, decision point 2028. O27 — Briquilimab still combined with fludarabine+TBI in all current trials: HIGH SEVERITY OPEN — no published trial demonstrates standalone non-genotoxic conditioning; CRITICAL PATH for Phase 1 in healthy subjects; decision point 2028-2030. O28 — Marsico et al. 2025 structural critique (Small Methods, IIT Naples) — "Not a single CAR-T cell therapy has reached regulatory approval for solid tumors": HIGH SEVERITY OPEN BY DESIGN — DQIS does not solve the four CAR-T solid-tumor challenges (off-tumor toxicity, immune resistance, infiltration, exhaustion) but redistributes them via quorum k=3/5 (binomial: per-channel pfail=0. 30 → system 0. 163, 1. 84× improvement) ; only Phase 0 PoC on melanoma B16F10 syngeneic model (€2-5M, 24-30 months) empirically rebuttable. Distribution by status: 11 RESOLVED, 2 LOW, 9 MEDIUM, 5 HIGH open (O7, O8, O14, O27, O28). High-severity open flaws require standard preclinical validation (O8, O14), industry maturation (O27), or empirical Phase 0 PoC (O28) — not conceptual breakthroughs. Read alongside Consolidated v24 and Addendum I v11. Not a peer-reviewed publication. Prior art deposit — CC BY 4. 0. Contact: dqis. research@proton. meRelated documents: - DQIS Consolidated Framework (main document): https: //zenodo. org/records/19877553 - Addendum I — Temporal Stratification of Tail Dependence Risk: https: //zenodo. org/records/19877810